Meta-group | APAF1 | |||||
---|---|---|---|---|---|---|
204859_s_at | 211553_s_at | 211554 _s_at | ||||
Expression Change | P Value | Expression Change | P Value | Expression Change | P Value | |
Blood neoplasm cell line (n = 166) | +/− | 0.282 | + | 5.37 × 10−7 | + | 1.09 × 10−8 |
Blood non neoplastic disease (n = 388) | + | <1 × 10−10 | + | 8.87 × 10−5 | + | <1 × 10−10 |
Breast cancer (n = 672) | − | <1 × 10−10 | − | <1 × 10−10 | − | <1 × 10−10 |
Germ cell neoplasm (n = 71) | +/− | 0.293 | − | 5.18 × 10−10 | +/− | 0.88 |
Leukemia (n = 567) | + | <1 × 10−10 | + | <1 × 10−10 | + | <1 × 10−10 |
Nervous system neoplasm (n = 112) | +/− | 0.059 | − | <1 × 10−10 | − | <1 × 10−10 |
Non breast carcinoma (n = 258) | − | 4.45 × 10−9 | − | 9.65 × 10−8 | − | 1.39 × 10−10 |
Non leukemic blood neoplasm (n = 334) | − | <1 × 10−10 | + | 2.55 × 10−8 | + | <1 × 10−10 |
Non neoplastic cell line (n = 262) | +/− | 0.954 | + | 0.012 | + | 0.025 |
Normal blood (n = 467) | + | <1 × 10−10 | + | 1.61 × 10−10 | + | <1 × 10−10 |
Normal solid tissue (n = 566) | − | <1 × 10−10 | +/− | 0.542 | − | 6.35 × 10−4 |
Other neoplasm (n = 167) | − | 1.71 × 10−5 | − | 1.62 × 10−5 | − | 7.2 × 10−6 |
Sarcoma (n = 104) | +/− | 0.233 | − | 2.16 × 10−7 | − | 0.017 |
Solid tissue neoplasm cell line (n = 831) | − | <1 × 10−10 | + | 1.52 × 10−6 | + | <1 × 10−10 |
Solid tissue non-neoplastic disease (n = 377) | − | <1 × 10−10 | +/− | 0.112 | +/− | 0.849 |
Assessment of APAF1 expression in the Human Gene Expression Map (Lukk et al., 2010). The database encompasses 5372 samples hybridized to the Affymetrix HG-U133A platform for comparison of the expression levels relative to 15 meta-groups. The number of samples is listed for the respective meta groups. Direction of change and P values, respectively, are indicated. Significant increased expression is indicated by plus (+), significant decreased expression indicated by minus (−) and non-differentially expressed is indicated by +/−. A P value of 0.05 was considered significant.